In particular, Galectin-1 (Gal-1) and Galectin-3 (Gal-3) act as regulators of inflammatory response in lung diseases such as COPD and idiopathic pulmonary fibrosis (IPF), making them good targets for drug design therapies [9,10,11]. This evidence concerns the gene LGALS1 and pulmonary fibrosis.